FDA Goes To Committee With Uncertainty About Metreleptin Efficacy For Partial Lipodystrophy
This article was originally published in The Pink Sheet Daily
Executive Summary
The Dec. 11 Endocrinologic and Metabolic Drugs Advisory Committee also will consider whether a proposed Risk Evaluation and Mitigation Strategy would address the possible risk for lymphoma and immunogenicity with Bristol-Myers Squibb/AstraZeneca’s drug.